Total
0
Shares
Kalytera Therapeutics receives positive results from drug study
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Skylight Health (SHG) partners with ClinEdge for clinical trials in the US
  • ClinEdge has over ten years of experience partnering with prominent research groups and sponsors
  • This partnership demonstrates the value of Skylight’s diversity in healthcare services across the United States
  • Based on the success in Massachusetts, Skylight will look to further expand this partnership across other US states
  • Skylight Health Group (SHG) is in the grey and is trading at C$1.32 at 1:02 pm ET

Skylight Health Group Inc (SHG) has announced a partnership with ClinEdge, one of North America’s leading clinical research groups.

ClinEdge provides a full suite of services to support clinical research institutions, Contract Research Organizations, and sponsors.

Their mission is to develop and grow service lines that positively affect the cost structure, timeliness and accuracy of administering clinical research.

Their relationships with CROs and other industry sponsors ensure the success of their Study Lead Generation Services to identify clinical trials to suit the population of each research site in their network.

ClinEdge works closely with clinical research sites to ensure their success in being awarded clinical research trials from highly experienced and well-known industry sponsors.

“Partnering with sponsors that share a similar vision on the importance of quality clinical research that puts patients first is vital to Skylight’s growth and the growth of the US healthcare system at large,” said Alisha Garibaldi, Clinical Research Manager, Skylight Health Group.

“ClinEdge brings unparalleled experience in this field, and we’re proud to have solidified this partnership,” added Garibaldi.

Based on Massachusetts's success, Skylight will look to further expand this partnership across other US states.

ClinEdge brings trial opportunities in a wide range of indications, including diabetes, COVID-19, arthritis, post-traumatic stress disorder, hypertension, and many others.

Patient participation in trials awarded to Skylight Health will be available for both existing patients and individuals who may not be patients of Skylight Health but are interested in contributing to clinical research.

The award for clinical research sites may range from $1,000 - $15,000 per patient per trial. Patients receive stipends to compensate for their time and effort for participating in clinical trials and reimbursements for expenses incurred.

ClinEdge and Skylight's teams carefully screen all trials for scientific and ethical rigour before reaching out to potential patients.

“We are excited to announce our partnership with ClinEdge as it is the next step in the expansion of our clinical research program," said Christopher Smith, SVP of Digital Health and Research, Skylight Health

"This partnership represents an opportunity for our clinics and patients to make meaningful contributions to the improvement of healthcare through clinical research while providing access to new therapies and the potential for subsidized care,” added Smith.

Skylight Health is a healthcare services and technology company working to impact patient health outcomes positively.

Skylight Health Group (SHG) is in the grey and is trading at C$1.32 at 1:02 pm ET.

More From The Market Herald
Leveljump (TSXV:JUMP) to acquire Ontario clinics

" Leveljump (TSXV:JUMP) to acquire Ontario clinics

Leveljump Healthcare (JUMP) is set to acquire three Ontario diagnostic imaging clinics from a private vendor.
CloudMD (TSXV:DOC) announces a change of auditors and new board of director nominees

" CloudMD (TSXV:DOC) announces a change of auditors and new board of director nominees

CloudMD has nominated Duncan Hannay and Karen Adams to the company’s board of directors.
Psyence Group (CSE:PSYG) and Pure Extracts (CSE:PULL) form psychedelics joint venture

" Psyence Group (CSE:PSYG) and Pure Extracts (CSE:PULL) form psychedelics joint venture

Pure Extracts (PULL) and Psyence Group (PSYG) have formed a JV for psychedelic medicinal mushroom extracts.
PharmaDrug (CSE:PHRX) announces meeting with FDA

" PharmaDrug (CSE:PHRX) announces meeting with FDA

PharmaDrug (PHRX) has been granted a pre-investigational new drug meeting with the FDA for its COVID-19 treatment.